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ABSTRACT 
The generation of vaccine-induced protection against infections relies on a well-coordinated 
network of innate immune responses, adaptive cellular responses, and humoral responses. 
Sufficient stimulation of the innate immune system by vaccination is critical to subsequently 
induce effective pathogen-specific T cell and B cell responses. The magnitude, characteristics 
and functions of the T cell and B cell response will further determine the protective effect of 
the vaccines. This thesis has investigated aspects of both the early innate immune response as 
well as the adaptive T cell and B cell response after vaccination. Specifically, the first part 
focuses on the functions of different innate myeloid cell subsets in regulating vaccine 
responses. The second part focuses on the antibody responses induced by a new live pertussis 
vaccine compared to the currently used acellular pertussis vaccine (aPV).  
Neutrophils are the major circulating myeloid cells. Heterogeneity and plasticity of neutrophils 
have received much attention during the past years. In Paper I, we show that neutrophils can 
present antigens to antigen-specific memory CD4+ T cells. This is dependent on the 
upregulation of MHC-II and costimulatory molecules on neutrophils which can occur in the 
presence of antigens and autologous antigen-specific memory CD4+ T cells. Furthermore, we 
found that neutrophils isolated from lymph nodes draining vaccine injection sites of rhesus 
macaques can present vaccine antigens to antigen-specific CD4+ T cells. Neutrophils may 
therefore play a role in the induction and regulation of vaccine-specific T cell responses through 
antigen presentation. 
There have been efforts trying to understand how vaccines induce immune responses but much 
less is known about immune suppressive regulation. In Paper II, we demonstrate that myeloid-
derived suppressor cells (MDSCs), which is a unique population of myeloid cells with 
suppressive functions particularly on T cells, accumulate transiently after vaccination. We 
found that monocytic (M)-MDSCs and polymorphonuclear (PMN)-MDSCs are present in 
rhesus blood and possess inherent suppressive effects on T cells. The frequency of M-MDSCs 
rapidly and transiently increased in the blood, and these cells infiltrated the injection sites after 
vaccination. We speculate that MDSCs contribute with an immune-balancing role to prevent 
excessive immune activation and inflammation upon vaccine exposure. 
In Paper III, we evaluated the immune responses in humans receiving the live attenuated 
Bordetella pertussis vaccine BPZE1 in a clinical trial. A single intranasal immunization of 
BPZE1 induced well-detectable plasmablasts, activated circulating T follicular helper cells, 
vaccine-specific Th1-polarized CD4+ T cells, memory B cells and antibodies. In contrast to the 
antibodies induced by the currently used aPV, BPZE1-induced antibodies showed substantially 
broader specificities to several B. pertussis antigens, many of which were identified for the first 
time. The BPZE1-induced antibodies were also more potent in mediating bacterial 
opsonization to stimulate reactive oxygen species production in neutrophils, which further led 
to enhanced bactericidal function.  
Collectively, these studies help in the understanding of how myeloid cells dictate immune 
responses and how the quality and specificities of antibody responses can be influenced by 
different pertussis vaccine platforms. This information will ultimately aid in the development 
of better future vaccines. 
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1 INTRODUCTION 
The history of immunization can be traced back to the 10th century in ancient China when 
inoculation was practiced by blowing powdered material from smallpox scabs into the nostrils1. 
In 1796 Edward Jenner inoculated pus from cowpox blisters into a boy and found him to be 
protected against smallpox2. Jenner’s attempt established the concept of vaccination and paved 
the way for vaccine research and development. Nowadays the field of vaccination has become 
multidisciplinary and covers aspects of immunology, biology, chemistry, pharmaceutics, and 
material science3,4. The past few decades being an active time for vaccine research have 
witnessed a remarkable development of vaccines, from traditional live-attenuated vaccines, 
inactivated vaccines, subunit vaccines, to nucleoid acid vaccines (DNA vaccines, mRNA 
vaccines, and recombinant vector vaccines), accompanied by a rapid development of vaccine 
delivery systems especially nanoparticle-based platforms5-7.  
Effective vaccines have saved many lives and contributed to the eradication of diseases such 
as smallpox8. Diseases such as polio and yaws are promising targets to be eradicated in the near 
future9. Vaccine-preventable diseases, i.e., diphtheria, measles, tetanus, and hepatitis B, have 
been greatly controlled under standardized immunization programs10,11. However, today we 
are still facing a lot of challenges in the fight against infectious diseases. Serious infections 
such as tuberculosis, HIV/AIDS, and malaria cause vast deaths worldwide and no fully 
effective vaccines are yet available12-14. Resurgence and outbreaks of vaccine-preventable 
diseases such as pertussis have occurred in recent years despite vaccination15, which indicates 
that some vaccines that we are using today need to be improved. The limited response to 
vaccination observed in immunocompromised individuals has indicated the need for better 
vaccines or more suitable vaccination strategies for specific populations16. In addition, vaccine 
research focusing on non-infectious conditions such as allergies, autoimmune diseases and 
cancers is emerging and still at its initial stage17,18. To tackle these challenges and drive the 
vaccine field forwards, we need to have a more thorough understanding of how vaccines 
interact with the immune system and the immune mechanisms dictating vaccine responses.  
When evaluating vaccines, it is a common practice to focus on the ultimate outcomes – the 
magnitude and quality of antibodies, T cell responses, and the resulting protection against 
infection. Effective protection induced by vaccines is multifactorial and requires an intimate 
collaboration between specific antibodies, T cells, and in most cases, also innate effector cells19. 
Upon administration into the host, vaccines first trigger the innate immune system20, which is 
structured by complements and distinct populations of innate immune cells that are widely 
distributed throughout the body. Innate immune activation subsequently leads to events such 
as a local production of inflammatory mediators (cytokines and chemokines), recruitment of 
cells to the sites of inflammation, activation of complement cascades, and the initiation of 
antigen presentation process21. The adaptive immune system, divided by humoral and cellular 
immunity, is considered to combat foreign threats more efficiently due to their high degree of 
diversity and specificity, as well as the memory capacity that enables them to quickly respond 
upon secondary antigen exposure. Humoral response is mediated by B cells that produce 
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specific antibodies functioning through neutralization, opsonization and activation of 
complements22. Cellular response is mediated by activated T cells that either differentiate into 
distinct effector subtypes producing cytokines or exert direct cytotoxic effects23. The degree of 
early innate immune reactions fundamentally determines the level of adaptive immune 
responses. In return, adaptive immune responses can synergize with innate immune system to 
mount a more efficient outcome. Therefore, it is important to understand the vaccine-host 
interactions and how innate and adaptive immune system cooperate to elicit sufficient vaccine-
specific responses. 
Using human and nonhuman primate (NHP) samples, I have in my Ph.D. thesis studied 
vaccine-host interactions and their effects on vaccine responses. The focus of this thesis was 
originally planned to be on two unique populations of innate myeloid cells (neutrophils and 
MDSCs), but after studying them in humans receiving a novel live attenuated B. pertussis 
vaccine, the work expanded to characterize antibody responses. In the end, the work revolved 
to analyze how the vaccine-induced antibodies affected neutrophils in their bacterial clearance 
process. Altogether, this work contributes to a better understanding of the mechanisms 
regulating pertussis immunity.  
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2 AIMS OF THESIS 
The overall aim of the thesis was to elucidate how innate myeloid cells (neutrophils and 
MDSCs in particular) influence vaccine responses and how different pertussis vaccines 
regulate the quality of antibodies which in turn affect the interaction with myeloid cells to clear 
bacteria. The specific aims of the individual studies were: 
 
Paper I: To study the antigen-presenting function of neutrophils in regulating vaccine-specific 
T cell responses  
 
Paper II: To characterize MDSCs in rhesus macaques and explore the role of MDSCs in 
vaccine-induced responses 
 
Paper III: To characterize the immune responses in humans receiving a live attenuated pertussis 
vaccine compared to the clinically used acellular pertussis vaccine 
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3 INNATE MYELOID CELLS 
Innate myeloid cells being the key components of the innate immune system contain 
monocytes, macrophages, granulocytes, mast cells, dendritic cells (DCs), thrombocytes, and 
erythrocytes24. These cells are derived from common myeloid progenitors (CMPs), which are 
in contrast to natural killer (NK) cells, gamma delta T cells and innate lymphoid cells that are 
rooted in the lymphoid lineage25. Upon vaccine administration, myeloid cells are the first to 
encounter vaccines26,27, undergo activation process, and initiate the succeeding immunological 
events to build vaccine-specific responses.  
3.1 NEUTROPHILS 
Neutrophils are the most abundant myeloid cells within the blood circulation in humans28. They 
are derived from granulocyte-monocyte progenitor cells (GMPs) that undergo sequential 
differentiation stages in the bone marrow (BM) and mature neutrophils egress into circulation 
when terminally differentiated29. At steady state, neutrophils circulate in the blood for a limited 
period of time (approximately 12h) before being cleared. This physiological process has 
recently been referred to as “neutrophil aging”, which follows a circadian rhythm and plays an 
important role in maintaining homeostasis30,31. When “danger signals”, such as infection or 
tissue damage, appear in peripheral tissues, circulating neutrophils are quickly alerted and 
usually represent the first cells migrating to the sites of inflammation. This is known as 
“extravasation” that involves multiple steps coordinated by adhesion molecules and 
chemokines28.  
As one of the major phagocytes, 
neutrophils are specialized at taking 
up pathogens, and subsequently 
eliminate them through oxidative 
burst or release of destructive 
antimicrobial proteins stored in 
granules32. In addition, neutrophils 
can extrude web-like structures 
containing nuclear chromatin and 
granule proteins, which are named 
neutrophil extracellular traps 
(NETs)33 that capture extracellular 
pathogens and degrade them (Figure 
1). However, the traditional view that 
the functions of neutrophils are restricted to the initial phase of the defense against pathogens 
has been changed34. A substantial body of evidence has demonstrated that there is a high 
diversity of neutrophils with regard to their versatile functions in partaking in both innate and 
adaptive immune responses35,36.  
Figure 1. Microbicidal mechanisms of neutrophils. 
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3.1.1 Heterogeneity of neutrophils 
Neutrophils have long been considered as a homogeneous population of terminally 
differentiated cells with a short lifespan. This view has been changing in recent years as studies 
demonstrated the heterogeneity and plasticity of neutrophils, which manifest as differences in 
phenotypes, maturation or activation status, locations, buoyancy, and importantly the 
functions29,37.  
Heterogeneous populations of neutrophils have been reported at steady state, as well as under 
inflammatory or pathological conditions. The aforementioned spontaneous neutrophil aging is 
a typical example showing the heterogeneity of circulating neutrophils in the absence of 
inflammation. Once released into the blood circulation, neutrophils undergo phenotypic 
changes over time, e.g. upregulation of CXCR4, CD11b and downregulation of CXCR2, until 
they become aged neutrophils and leave the circulation38. Although the physiological 
consequence of neutrophil aging is largely unknown, the altered expression of certain surface 
molecules related to cell adhesion may affect their trafficking and migration into peripheral 
sites. In addition to neutrophils at different age, phenotypically different neutrophil subsets 
exist in the blood under homeostasis. In healthy individuals, a proportion of mature neutrophils 
express CD177, a glycoprotein that mediates the interaction between neutrophil and endothelial 
cells38,39. In addition, 20-25% circulating neutrophils possess the expression of olfactomedin-
4 (OLFM4)40 and these cells are more prone to produce NETs as compared to their OLFM4- 
counterparts41. Recent evidence also demonstrated the presence of neutrophils in multiple 
tissues under normal conditions, which challenged the traditional understanding that tissues are 
devoid of neutrophils42. In healthy individuals, neutrophils are found in the lung vasculatures  
constituting the “marginated pool”43. These cells resemble aged neutrophils and highly express 
CXCR4, which allows them to be retained in the lung through the interaction with CXCL12 
released by pulmonary endothelia cells44. In the spleens of healthy humans and mice, a unique 
population of neutrophils located around marginal zone exhibit B cell helper functions and 
produce cytokines such as B cell activating factor (BAFF) and a proliferation-inducing ligand 
(APRIL) to regulate antibody production45,46. Neutrophils have also been found in many other 
healthy tissues, while the biological relevance is largely unknown42. Whether these neutrophils 
transiently appear in tissues before being cleared or they are bona fide cells able to reside long 
term to exert unique functions are still unknown47.  
Heterogeneity of neutrophils is more commonly seen in pathological conditions35. This is 
largely due to an abnormal granulopoiesis process, during which several neutrophil subsets 
with different levels of maturity are generated and released to the circulation or peripheral 
tissues48. In the blood, heterogeneity of neutrophils is usually reflected by the difference in 
buoyancy. During inflammation, a population of neutrophils co-localize with peripheral 
mononuclear cells (PBMCs) after density gradient centrifugation using Ficoll (1.077g/L)49. 
These neutrophils are referred to as low-density neutrophils (LDNs), in contrast to the normal-
density neutrophils (NDNs) that sediment together with erythrocytes. LDNs normally contain 
immature and mature cells indicated by the different morphology and phenotype (Figure 2). 
These cells may increase in numbers in the context of infection, cancer, or other disorders and 
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their frequencies may correlate with disease progression50,51. Of note, a unique population of 
cells, mostly known as PMN-MDSCs, with suppressive functions on T cells may exist in the 
LDN pool52. Much effort has been put on identifying unique markers for PMN-MDSCs. Recent 
evidence indicated lectin-type oxidized low-density lipoprotein receptor-1 (LOX-1) to be a 
specific marker for PMN-MDSCs, at least in cancer patients53. In contrast with LDNs, NDNs 
are usually considered as a homogeneous population of mature cells under homeostasis. 
However, NDNs may represent a heterogeneous population in non-homeostatic conditions. For 
example, CD10+ NDNs and CD10- NDNs were reported in the blood of healthy individuals 
receiving G-CSF treatment for stem cell mobilization, and these two subsets possess inhibitory 
and stimulatory effects on T cells, respectively54. Apart from the cells in the circulation, 
heterogeneous tissue-infiltrating neutrophils have also been described in pathological 
conditions. One typical example is tumor-associated neutrophils (TANs)55,56 that include anti-
tumorigenic (N1) and pro-tumorigenic population (N2). However, as the discrimination of N1 
and N2 is mainly based on their functional difference, identification of unique surface markers 
is still needed.  
 
Figure 2. Heterogeneity of neutrophils in human blood. 
3.1.2 Neutrophils as antigen-presenting cells (APCs)  
The functions of neutrophils in regulating T cell responses through antigen presentation have 
attracted considerable attention recently57,58. Early evidence of the antigen-presenting ability 
of neutrophils mostly came from in-vitro studies showing that IFN-γ or GM-CSF-stimulated 
neutrophils could express MHC-II and co-stimulatory molecules (CD80 and CD86), and 
thereby stimulating T cell proliferation59,60. It was also shown that GM-CSF-treated human and 
murine neutrophils could differentiate into hybrid cells with dual features of dendritic cells 
(DCs) and neutrophils61,62, implying a potential antigen-presenting ability of these cells. 
Similar evidence that neutrophils could express HLA-DR was also observed in patients 
receiving GM-CSF or IFN-γ treatment63,64. In these contexts, cytokine-induced expression of 
MHC-II on neutrophils is mainly mediated by the activation of class II transactivator (CIITA), 
a key regulator controlling MHC-II transcription65.  
In addition to the findings that cytokine-treated neutrophils can function as APCs, several 
recent studies including ours (Paper I) showed that T cells could deliver signals to neutrophils 
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that provided them with antigen-presenting functions66-68. We have shown that freshly isolated 
neutrophils can acquire the expression of HLA-DR, CD80 and CD86 when co-cultured with 
antigens and autologous antigen-specific memory T cells. This enables them to present the 
antigens to antigen-specific T cells, thereby stimulating proliferation and cytokine production 
of T cells68. Similarly, mouse studies showed that neutrophils loaded with ovalbumin (OVA) 
were able to present the antigen to OVA-specific T cells and drive the expansion of effector T 
cells67. Of note, no evidence so far shows that neutrophils can prime naïve T cells, which is a 
typical feature of classical APCs such as myeloid DCs. Therefore, neutrophils are considered 
as atypical APCs restrictive to the regulation of memory T cells69. While the exact signals 
delivered from memory T cells to neutrophils still are unclear, possible candidates are the 
cytokines released by bystander-activated T cells. It is likely that neutrophils are triggered by 
cytokines released from T cells that are activated by other neighboring APCs (Figure 3). In 
addition, surface antigen-mediated cell-cell contact between memory T cells and neutrophils 
may also play a role, for example, the binding of intercellular adhesion molecule I (ICAM-1) 
on memory T cells to CD11b/CD18 on neutrophils. This initial cell-cell interaction may 
provide “prime” signals to evoke MHC-II expression by neutrophils58. In addition to these, 
some other mechanisms may exist.  A very recent study showed that neutrophils could acquire 
the function of APC after they phagocytosed antibody-opsonized erythrocytes70. In this 
scenario, fresh neutrophils are able to express MHC-II and costimulatory molecules even in 
the absence of T cells or cytokine stimuli (Figure 3).    
 
Figure 3. Potential mechanisms involved in the induction of APC feature by neutrophils. 
In conclusion, the antigen-presenting function of neutrophils starts to be a well-established 
phenomenon. However, the physiological or pathological significance of this remains to be 
understood. Although neutrophils cannot compete with classical APCs in their capacity of 
antigen presentation on a per cell basis, their abundance may make up for some of the weak 
ability.  
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3.2 MYELOID-DERIVED SUPPRESSOR CELLS (MDSCS) 
MDSCs are a heterogeneous population of myeloid cells that demonstrate strong suppressive 
function on T cells71. They are considered as activated immature cells that cannot fulfil normal 
differentiation in the BM due to an aberrant myelopoiesis. MDSCs appear in a variety of 
conditions associated with cancer, infections, autoimmune diseases or other disorders72. For 
example, they are generated in the BM and spread to periphery in response to tumor-secreted 
growth factors73 such as granulocyte colony stimulating factor (G-CSF), IL-6, prostaglandin 
E2 (PGE2), tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) (Figure 
4). The roles of MDSCs in the pathology of these immune-related diseases are not fully 
understood and appear to be heterogeneous. 
 
Figure 4. Differentiation and function of MDSC populations observed in cancer patients. 
3.2.1 Heterogeneity of MDSCs 
The immune regulatory functions of MDSCs have been well documented. However, current 
understanding of their heterogeneity is still elusive, in particular regarding their phenotypes74. 
MDSCs have intensively been studied in humans and mice (Figure 5). In Paper II of this thesis 
we characterized these cells in NHPs (rhesus macaques)75. Human MDSCs do not express the 
lineage (Lin) markers CD3, CD19 or CD56 but typically express CD11b and CD33, and have 
low or absent expression of HLA-DR. They can be further divided into three major subsets: 
monocytic (M)-MDSCs, polymorphonucelar (PMN)-MDSCs and early-stage (E)-MDSCs. 
Amongst them, M-MDSCs and PMN-MDSCs have been much investigated and they are 
present in humans, mice and NHPs76. E-MDSCs have recently been termed in humans, but this 
subset has yet to be defined in animal models77. 
In humans, M-MDSCs are normally identified as HLA-DR-/lowCD14+ cells. CD11b and CD33 
are also highly expressed by M-MDSCs and therefore can be used as additional markers to 
identify them52. Being considered as the counterparts of monocytes, M-MDSCs share the 
morphology and surface markers with monocytes to a large degree, such as CD11b, CD33 and 
CCR275. Therefore, phenotypic discrimination of M-MDSCs from monocytes is normally 
determined by the lack of HLA-DR expression. What remains to be investigated is whether M-
MDSCs and monocytes are generated in different differentiation pathways or if M-MDSCs are 
simply a subpopulation of monocytes acquiring suppressive function in diseases. PMN-
MDSCs are immature neutrophils present inside LDNs. Identification of PMN-MDSCs 
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remains to be a challenge due to the lack of unique markers78. Human PMN-MDSCs have 
therefore long been defined as LDNs, which are typically identified as CD15+CD33dimSSChigh 
cells that resemble NDNs except for their lower buoyancy52. Recently, LOX-1 was 
demonstrated to be a unique marker for PMN-MDSCs in patients with non-small cell lung 
cancer and head and neck cancer53. Whether this can be applied to other disease models remains 
to be validated. To this end, in the MDSC field it has been widely accepted that functional 
assessment of potential MDSCs following purification based on surface markers is the “gold 
standard” to identify them. 
 
Figure 5. Phenotypes of MDSCs in humans, mice and rhesus macaques. 
Apart from the cell morphology and phenotype, some intrinsic differences exist between M-
MDSCs and PMN-MDSCs. Compared with PMN-MDSCs, M-MDSCs are more potent at 
excreting suppressive effects79. They possess a longer lifespan and are more tolerable to freeze-
thaw procedures80, which adds the technique feasibility to study them. In addition, M-MDSCs 
can be generated from monocytes in vitro upon stimulation with cytokines such as GM-CSF 
and IL-681. M-MDSCs also maintain some degree of plasticity to further differentiate to non-
suppressive cells82. For example, TLR7/8 agonists can induce human M-MDSCs to 
differentiate to macrophages83. So far, there is no such evidence showing the plasticity of PMN-
MDSCs. 
3.2.2 MDSCs in diseases and inflammation 
The most well-known function of MDSCs is their suppressive effect on T cells. This is mainly 
mediated by two mechanisms84 namely secretion of suppressive mediators (e.g. arginase-1, 
inducible nitric oxide synthase) and expression of co-inhibitory molecules (e.g. PD-L1). Aside 
from these, MDSCs can cross talk with other immune cells to negatively regulate immune 
responses. For instance, MDSCs have been shown to promote the expansion of regulatory T 
cells (Treg)85, suppress NK cell cytotoxicity as well as inhibit the maturation of DCs86.  
The role of MDSCs appears to be widespread in different diseases. Being first reported in tumor 
models, MDSCs have intensively been studied in the context of cancer73. Elevated levels of 
MDSCs in the blood, tumor microenvironments, and lymphoid organs have been described in 
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a variety of malignancies84. Their suppressive effects impair anti-tumor T cell responses and 
were shown to support tumor progression. The level of MDSCs has been proposed to be a 
predictor of poor prognosis and is associated with poor survival in patients with breast, 
pancreatic, melanoma and colon cancer87-90. Therefore, strategies to block MDSC expansion, 
disturb inhibitory mechanisms, promote MDSC maturation, as well as prevent their migration 
to tumor sites have been employed in the development of therapeutic drugs and treatment of 
cancer91. For examples, sunitinib, being used in the treatment of renal cell carcinoma, can block 
the signal transducer and activator of transcription (STAT3) pathway to inhibit MDSCs 
expansion92. All-trans retinoic acid (ATRA) that can induce the differentiation of MDSCs into 
non-suppressive DCs is used to treat acute promyelocytic leukemia in clinic93,94. 
In contrast to the wealth of information on MDSCs in cancer, the roles of MDSCs in several 
other pathological or inflammatory conditions have recently emerged as an intense area of 
investigation95. Much has been studied was the functions of MDSCs during infections96. 
Accumulating evidence demonstrated the expansion of MDSCs under conditions of bacterial, 
viral, fungal and parasitic infection97. However, their respective role remains diverse in 
different contexts. Taking advantage of the suppressive function, MDSCs can help to counter-
balance overwhelming inflammation to prevent tissue damage. However, an excessive 
expansion of MDSCs may impair the anti-infection immunity of the host, thereby favoring 
pathogen persistence and inducing chronic infection. MDSCs therefore function as “double-
edged sword” in the context of infection98. Whether they are beneficial or detrimental for the 
host depends on the type of infection and stage of diseases.  
MDSCs are also associated with several inflammatory conditions. In individuals with obesity, 
MDSCs are elevated as a consequence of low-grade persistent inflammation. This has been 
proposed to explain why obese populations showed compromised immune responses to 
vaccination99. Accumulation of MDSCs was also observed in experimental hypertension 
mice100. In this scenario, MDSCs can help alleviate high blood pressure and limit inflammation 
through the production of ROS. MDSCs also play a critical role in maintaining maternal-fetal 
tolerance to ensure normal pregnancy101. Vaccination-elicited inflammation was also shown to 
induce MDSCs, which in turn negatively influenced the vaccine efficacy102. Consistently, GM-
CSF, an adjuvant used in a melanoma cancer vaccine formulation was reported to induce 
MDSCs and thereby impaired the therapeutic outcome103. These studies prompted a 
relationship between MDSCs and vaccination. A further investigation on this would increase 
our understanding of any interfering role that MDSCs may have in vaccination. 
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4 ANTIBODY RESPONSES 
While the innate immune system can provide a rapid protection in face of infections, their 
contribution is usually limited. Adaptive immune responses built on the innate system are 
therefore needed to confer more effective and specific protection. Moreover, the memory 
capacity of the adaptive immune system allows it to quickly respond upon successive antigen 
exposure. In the context of vaccination or infection, the antibody response, being one arm of 
the adaptive immune system, is of particular importance. Almost all the vaccines to date 
function through the induction of specific antibodies in the serum or on the mucosal surface to 
combat infections. It has been well documented that vaccine-elicited antibody responses 
dominantly determine the ultimate outcome and, in many cases, operate as correlates of 
protection104. For any pathogen, a vaccine that could induce a broad, long-term antibody 
response with high neutralizing capacity would be able to confer efficient protection.  
4.1 DEVELOPMENT OF ANTIBODY RESPONSES 
B cell progenitors in the BM go through several successive steps including immunoglobulin 
(Ig) gene rearrangement, negative selection and finally differentiate into naïve B cells emerging 
into the periphery. Naïve B cells continuously patrol the blood circulation and the lymphatic 
system until encountering their cognate antigens in the spleen or LNs, whereupon they continue 
their maturation and differentiation program, which ultimately leads to the establishment of 
antibody responses105,106.  
Naïve B cells carry surface IgM and IgD as B cell receptors (BCRs) to sense the pathogenic 
antigens107. Some microbial components can directly stimulate B cells to produce antibodies 
without the help from T cells108. These antigens are named as thymus-independent (TI) 
antigens that can be divided into two groups: TI-1 antigens, which possess intrinsic B-cell 
activating capacity such as lipopolysaccharide (LPS), and TI-2 antigen109, which contain highly 
repetitive epitopes such as polysaccharide antigens. Antibody responses induced by TI antigens 
can provide early protection but are usually considered less efficient due to no or limited 
somatic hypermutation (SHM) and class switching. In contrast, antibody responses generated 
with the involvement of T-helper cells are endowed with higher diversity and better 
efficacy110,111. In this scenario, B cells function as APCs and can process antigens and present 
them to T follicular helper (Tfh) cells that have encountered the same cognate antigens during 
an earlier antigen presentation process mediated by DCs. As a consequence, activated Tfh cells 
deliver helper signals to B cells to promote cell proliferation, survival, differentiation, as well 
as the succeeding SHM and class switching112. These signals are present in the form of either 
cytokines such as IL-21 or expression of surface molecules such as CD40L and inducible T-
cell co-stimulator (ICOS) that interact with corresponding receptors on B cells113. Some of the 
B cells receiving helper signals will differentiate into short-lived antibody-secreting 
plasmablasts that constitute an initial phase of the antibody response. The remaining B cells, 
together with their cognate Tfh cells, will migrate into lymphoid follicles and form the germinal 
center (GC), where activated B cells undergo affinity maturation and class switching with the 
involvement of Tfh cells112. The GC reaction114,115 ultimately leads to the induction of long-
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lived plasma cells secreting a diverse repertoire of high-affinity antibodies and the generation 
of a memory B cell pool, which are also the goals of a successful immunization regimen.  
4.2 FUNCTIONS OF ANTIBODIES 
The whole antibody pool is composed of five antibody isotypes (IgM, IgD, IgG, IgA and IgE), 
distinguished by their difference in the constant region of the heavy chain116,117. Antibodies are 
distributed selectively throughout the body and exert specific functions in the context of 
infections. IgM is the first antibody produced and is present in the blood as a pentamer118. 
Soluble IgD is present at a very low level in the blood and its function remains unknown. 
However, surface IgD on B cells was shown to regulate B cell survival via BCR signaling119. 
IgG is the most abundant antibody isotype in the blood, as well as in the extracellular fluids. 
Four IgG subclasses exist, namely IgG1, IgG2, IgG3, and IgG4. Each subclass differs in their 
constant region and therefore possesses different functional activities120. IgA molecules exist 
either as monomers in the blood or as secreted IgA (sIgA) in a dimeric form present at mucosal 
surface and in secretions such as breast milk and saliva121. IgE is rare in the serum, but is closely 
associated with allergic reactions. IgE mainly works through the ligation with Fc receptors on 
mast cells and basophils, thus stimulating the cells to release functional mediators122.    
 
Figure 6. Overview of pathogen elimination mechanisms of antibodies  
Antibodies mainly exert their effects through three mechanisms: neutralization, opsonization, 
and complement activation (Figure 6). Neutralization is mediated by the intrinsic binding 
capacity of antibodies to the corresponding pathogen epitopes, which leads to the inhibition of 
the infectivity and pathogenesis of pathogens22. Several different ways of neutralization have 
been described116. The most common type of neutralization is mediated by the antibodies that 
bind to adhesins on pathogens and therefore interfere with their attachment to target cells. In 
addition, antibodies, especially polymeric IgM and IgA, can bind to pathogens and induce 
aggregation123,124. Some antibodies can immobilize the pathogens and impede their random 
movement125. In some cases, neutralizing antibodies can directly inhibit the growth of 
pathogens or even kill them by forming pores on the outer membrane upon surface binding126. 
Among the various antibody classes and subclasses, IgG and IgA are strong neutralizing 
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antibodies due to their high binding affinity (Table I). While IgM has a low neutralizing ability 
on a per molecule basis, it is compensated by the avidity effect of its pentameric form. In 
contrast, IgD and IgE have no neutralizing capacity. 
Beyond neutralization, the collaboration between antibodies and innate effector cells provides 
more efficient clearance of infections, especially for pathogens that cannot be neutralized by 
antibodies22. To this end, innate phagocytes such as neutrophils and macrophages are critical 
for host defense due to their surface expression of Fc receptors that bind to the Fc portion of 
antibodies127. The formation of immune complexes (ICs) as a result of binding between 
pathogens and antibodies can subsequently initiate a biological process referred to as 
“opsonization”, through which the pathogens are phagocytosed and eliminated by effector cells 
via Fc receptor ligation. This is of particular importance as some pathogens are naturally 
resistant to phagocytosis128, however, upon opsonization by antibodies, they can easily be 
recognized by effector cells. For example, in Paper III we showed that vaccine-induced 
antibodies can facilitate the clearance of B. pertussis by neutrophils through opsonization in 
vitro. In terms of opsonization, the different antibody isotypes and subclasses differ in their 
capacity (Table I). IgG1 and IgG3 are the most potent opsonizing antibodies due to their high 
binding affinity to Fc receptors.   
Table I. Antibody isotypes and subclasses differ in their functions 
 
Antibodies can also function in synergy with the complement system129. It is important to note 
that only the classical complement pathway, being one of the three complement activation 
cascades, is associated with antibodies. In this scenario, antibodies first bind to pathogens to 
form ICs and then the ICs bind to the complement component C1 to initiate the classical 
complement activation, which ultimately generates molecule C3b. After that, C3b molecules 
are deposited on pathogens and form C3b-pathogen complexes, which can be recognized by 
complement receptors (CRs) expressed by phagocytes, and as a consequence being 
phagocytosed and eliminated by the cells. In addition, C3b can bind to C3 convertases to 
continue the complement cascades and finally generate other complement molecules including 
C5b, C6, C7, C8, and C9. These molecules assemble together to form the membrane attack 
complex (MAC), which creates a pore on the outer membrane of pathogens and leads to the 
lysis and death of organisms. While the antibody-dependent activation of classical complement 
pathway is not the only way to generate the MAC, this effect can be further promoted by 
specific antibodies. For example, several studies including ours (Paper III) showed that 
complement killing of B. pertussis can be promoted in the presence of vaccine-induced 
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antibodies. Amongst the different antibody molecules, IgM is the most potent at activating the 
complement especially when polymeric IgM is formed.     
A major focus of investigation is to determine the immune correlates of protection in the case 
of vaccination or infection104. A better understanding of the correlates of protection can help 
us understand what type of immune response is favorable and therefore provides references for 
rational vaccine design. Early evidence has indicated that antibody titers can function as 
correlates of protection for pathogens such as tetanus and diphtheria130. However, for many 
infectious diseases, such as malaria, pertussis, and HIV, there is yet no consensus on definitive 
and quantitative immune correlates of protection. Therefore, instead of solely relying on the 
quantity, functional characteristics of antibodies may more likely serve as the candidates 
associated with protection. For example, recent evidence suggested that levels of complement-
fixing antibodies were associated with protection in the case of malaria131.  
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5 PERTUSSIS AND PERTUSSIS VACCINES 
Pertussis, also known as whooping cough, is a highly contagious respiratory disease caused by 
gram-negative bacterium Bordetella pertussis132. During the pre-vaccine era, pertussis was one 
of the major causes of infant morbidity and mortality. Nowadays, pertussis has been largely 
controlled thanks to the wide use of vaccines. That being said, it still remains to be one of the 
major vaccine-preventable diseases, which affects infants and young children frequently15.  
5.1 HISTORY OF PERTUSSIS VACCINATION 
The pertussis vaccine is usually combined with the vaccines against tetanus and diphtheria. 
These together form a combinatorial vaccine named DTP, which usually includes aluminum 
as the adjuvant. The first generation of the pertussis vaccine, whole cell pertussis vaccine 
(wPV), was developed in the 1930s and contained the entire formalin-killed bacterium133. 
During the 1940s in the United States (US), wPV was introduced and used in babies and young 
children with a high coverage as a routine immunization (Figure 7). In Europe, routine 
vaccination with wPV started in the late 1950s134. Since the wPV was globally used, pertussis 
became largely in control and the incidence almost dropped by 99%135. However, it was later 
noticed that wPV tended to induce adverse reactions, both locally and systemically. Especially, 
there was a possible association between the use of wPV and the occurrence of chronic 
neurological damages and encephalopathies, which raised a major concern in the public135. 
Because of the high reactogenicity, the use of wPV was reduced or even discontinued in some 
countries135. One example is that in Sweden the pertussis vaccination program was suspended 
from 1979 to 1996. This had resulted in two outbreaks of pertussis in 1983 and in 1985 in 
Sweden136. In countries with reduced coverage of wPV, there was also a sharp increase in the 
incidence of disease137.  
 
Figure 7. Overview of pertussis vaccination history and reported pertussis cases in the US  
To tackle these problems, the next generation of pertussis vaccine, an acellular pertussis 
vaccine (aPV) was developed during the 1980-1990s133. aPV contains one to five inactivated 
B. pertussis immunogens in different combinations, accompanied by aluminum as an adjuvant. 
The most commonly used aPV formulation is a 5-component vaccine including pertussis toxin 
(PT), filamentous hemagglutinin (FHA), pertactin (PRN), fimbriae 2 and fimbriae 3 (FIM2/3). 
aPV has now taken the place of wPV in the majority of industrialized countries. However, in 
less developed areas wPV is still being used because of the lower cost138. During the past 
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decades, an extensive course of immunization with aPV has provided a good level of protection 
and to a large extent controlled the disease139. However, it was noted that the incidence of 
pertussis has been growing during the last ten years even in industrialized countries with 
sustained vaccination history133,140. Some countries have even experienced outbreaks of 
pertussis occurring within school-age children that represent a highly-vaccinated population133. 
Further studies demonstrated that aPV-immunized individuals were more susceptible to B. 
pertussis infection compared to wPV-immunized people141. This has raised new concerns about 
the prevention of pertussis, especially the effectiveness of the current aPV142,143. Therefore, we 
are still facing the problem to develop more effective pertussis vaccines, which requires a more 
comprehensive understanding of pertussis immunity.  
Recently, a live attenuated B. pertussis vaccine, BPZE1, was developed and has been tested in 
several animal studies144-146, as well as in two human clinical trials (Jahnmatz, et al. In 
preparation)147. This live vaccine has been shown to elicit effective mucosal and systemic 
immune responses, long-lasting protection, and blocking of nasal colonization upon infection 
in animal models. In human clinical trials, BPZE1 showed excellent safety profiles and 
promising immunogenicity. In Paper III, we performed multiple analyses to in-depth 
characterize the immune responses in humans generated to BPZE1.  
5.2 PERTUSSIS IMMUNITY 
So far, considerable progress has been made to understand how the immune system responds 
to B. pertussis infection. Three major steps are involved in the pathogenesis and the induction 
of host immunity (Figure 8): (a). Attachment of B. pertussis to the lung epithelium and 
formation of colonies, (b). Release of toxins that cause tissue damages, inflammation and 
immune cell infiltration, (c). Induction of systemic adaptive immune responses. Substantial 
evidence has demonstrated that effective protection against B. pertussis is multifactorial and 
requires both specific antibodies and T cell responses, in synergy with innate effector cells148. 
5.2.1 Innate immunity to B. pertussis 
B. pertussis, as a respiratory pathogen, invades the host by attaching to the lung epithelial cells 
through adhesins such as FHA and PRN, which allows them to further grow and colonize the 
epithelium. This is usually accompanied by the release of virulence factors, such as 
dermonecrotic toxin (DNT) and tracheal cytotoxin (TCT), which cause local tissue damage and 
generate inflammation149,150. Following B. pertussis infection, the innate immune system is first 
alerted151. Complement molecules present on mucosal surface of upper respiratory 
compartments usually provide the initial phase of defense. However, B. pertussis has developed 
a range of strategies to evade complement killing152. One typical mechanism is the production 
of BrkA (Bordetella resistance to killing A) that inhibits the deposition of complement 
molecules on bacterial surface153.  
Following the reaction of complement system, local production of inflammatory molecules and 
infiltration of immune cells to the sites of infection are the succeeding innate immune events. 
In mice and baboons, B. pertussis infection was shown to induce an early production of 
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inflammatory cytokines (IL-6, IL-8 and IL-1β) and chemokines (monocyte chemoattractant 
protein-1, MCP-1 and macrophage inflammatory protein 1 alpha, MIP-1α) in the 
nasopharynx154,155. Infection of naïve mice with B. pertussis resulted in an early infiltration of 
DCs and macrophages into the lung, followed by an influx of neutrophils and NK cells148. DCs, 
being professional APCs, can recognize pathogen-associated molecular pattern (PAMPs) 
molecules on B. pertussis, take up the bacteria, undergo cell activation/maturation, and finally 
activate cognate T cells via antigen-presentation. A unique subset of DCs (CD11c+CD8α+ DCs) 
are highly involved in the generation of Th1 cell response against B. pertussis156. In addition, 
DCs primed by ACT were able to induce pertussis-specific Th17 response through the 
activation of inflammasome and IL-1β production157. Macrophages, being potent phagocytes 
with inherent bactericidal ability, also play a role in clearing B. pertussis. Their killing activity 
can be further augmented by IFN-γ and IL-17158,159. However, ACT was shown to induce the 
apoptosis of macrophages160,161. Some evidence also showed that B. pertussis can evade the 
killing by macrophages and replicate in macrophages by residing in non-acidic compartments 
within the cells, suggesting that macrophages may serve as intracellular haven for B. 
pertussis162.  
 
Figure 8. Pathogenesis of B. pertussis and the induction of host immunity 
In naïve mice, neutrophils are not the first wave of cells migrating to the local sites following 
B. pertussis infection163. This is mainly attributed by the toxins released by B. pertussis that 
inhibit chemotaxis, for example PT and ACT164,165. In addition, ACT can inhibit phagocytosis 
and oxidative burst of neutrophils, thus impairing their killing functions, which was proposed 
to be one major strategy of immune evasion by B. pertussis166. This explains why neutrophils 
are not helpful in clearing B. pertussis at early stage following infection in naïve mice. 
However, neutrophils are the key players to clear infection in convalescent mice, which is 
caused by the presence of pre-existing antibodies that can neutralize the immune-inhibitory 
toxins and opsonize bacteria to form ICs that facilitate phagocytosis163. Although some 
evidence showed that B. pertussis can also survive within subcellular structures in 
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neutrophils167, it is unlikely that neutrophils serve as intracellular reservoirs for B. pertussis due 
to their relatively short lifespan. In addition, in-vitro evidence demonstrated that fresh 
neutrophils possess killing capacity of B. pertussis, which can be further promoted upon 
stimulation with cytokines that activate neutrophils168,169.  
So far, limited information is available regarding the innate immune responses in vivo 
following intramuscular (i.m.) administration with wPV or aPV. However, it is possible that 
injection of wPV or aPV into the muscle sites can induce local inflammation and immune cell 
infiltration, which are typical innate immune events observed in other similar contexts26,170. 
wPV contains the whole organism that includes a wide range of molecules with inherent 
immune-stimulatory functions. Even the limited antigens included in aPV formulation are able 
to activate innate immune system. For example, PT and ACT can activate human monocyte-
derived DCs in vitro171. In contrast to wPV and aPV, BPZE1 as live attenuated bacteria 
administrated via intranasal route is supposed to elicit similar innate immune signatures as by 
natural infection. Of note, BPZE1 produces the inactive form of PT that does not have 
inhibitory effect on chemotaxis of neutrophils. This leads to that intranasal administration of 
BPZE1 into naïve mice can induce influx of neutrophils to the lung at early time points172, 
which is not observed in naïve mice challenged with virulent B. pertussis as mentioned. 
5.2.2 Antibody responses to B. pertussis 
Following B. pertussis infection, antibodies slowly develop and usually reach the peak after 4 
weeks. Early studies showed that passive transfer of serum from convalescent mice conferred 
a level of protection in sublethally irradiated mice173. Similarly, passive transfer of serum from 
wPV- or aPV-immunized mice conferred effective protection in naïve mice upon virulent 
challenge174. Further studies demonstrated that antibodies specific to PT and PRN mainly 
contributed to the protection174. The protective function of B. pertussis-specific antibodies was 
also described in humans where infected children receiving anti-B. pertussis Ig treatment had 
demonstrated a less duration of symptom175. 
The duration of the protective response against pertussis after infection or vaccination has been 
estimated176. It is believed that neither natural infection nor vaccination is able to elicit lifelong 
protection. The estimated duration of protection conferred by infection ranges from 7 to 20 
years. wPV-induced protection was speculated to persist for 4-14 years, which is longer than 
that induced by aPV (3-10 years). It is therefore believed that waning immunity induced by 
aPV is the major cause of pertussis resurgence139. However, studies showed that by 2 years 
following infection or vaccination with wPV or aPV, titers of pertussis-specific antibodies are 
barely detectable, whereas the protective activity remains176. This suggests that it is not only 
the antibody titer that should be taken into consideration when evaluating protective responses, 
the quality and functionality of antibodies may be equally important. This also raises another 
question about the immune correlates of protection against pertussis that is yet to be defined. 
Although early clinical data suggested that the anti-PT, PRN, FIM IgG level was indicative of 
protection177, there is still no consensus on this and no reliable threshold has been 
established130,178. Since B. pertussis has a complex antigen composition and a large proportion 
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of antigens overlap with other pathogens, it is likely that other immunogenic antigens 
associated with protection exist. To this end, I have in my studies (Paper III) identified novel 
B. pertussis immunogens that may potentially be related to protection. 
Functions of antibodies are mediated by the aforementioned mechanisms and are closely 
related to the antibody isotypes and subclasses (Table I). IgG being the most abundant antibody 
has been well investigated in both humans and animal models in the context of infection or 
pertussis vaccination. Infected mice or wPV-immunized mice showed a higher level of IgG2, 
IgG3 and lower level of IgG1 against B. pertussis antigens when compared to aPV-immunized 
mice179. In humans, IgG1 was elevated in both wPV- and aPV-immunized individuals. IgG4 
was only induced in subjects receiving repeated aPV immunization, whereas the induction of 
IgG3 was only seen in subjects primed with wPV180. Altogether, this suggests that a Th1- and 
Th2-polarized antibody response is generated by wPV and aPV, respectively (Figure 9). The 
four IgG subclasses differ in their ability in opsonization and complement activation, which 
may contribute to the different efficiency of wPV and aPV. In Paper III, we dissected the 
antibody responses induced by BPZE1 compared to that induced by aPV. BPZE1- and aPV-
immunized individuals developed Th1 and Th2 type antibodies, respectively. We found that 
this further led to that BPZE1-induced antibodies were more potent to stimulate reactive 
oxygen species (ROS) production in neutrophils and enhance bactericidal function.   
 
Figure 9. Types and quality of immune responses induced by B. pertussis infection or 
immunization with different types of pertussis vaccines 
Apart from IgG, IgA is also important to control B. pertussis infection, especially the secretory 
IgA (sIgA) residing at mucosal sites. It has been shown that both wPV and aPV are not able to 
elicit serum IgA in naïve mice, whereas natural infection does so179. The findings that wPV- or 
aPV-immunized individuals could develop an IgA response are largely attributed to their 
earlier natural exposure181. However, it is important to note that the route of vaccine 
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administration may influence the generation of IgA response. An intranasal administration of 
wPV was shown to induce both IgA in serum and sIgA in nasal fluid182. A recent study showed 
that even aPV, when given via intranasal route, could elicit protective sIgA response in mice183. 
These provide new vaccination strategies that could be utilized to improve vaccine efficacy.  
5.2.3 T cell responses to B. pertussis 
While an antibody response is critical for combating B. pertussis infection, it may not be 
sufficient to provide a fully protective response. It has been shown that effective protection 
against pertussis requires both specific antibodies and CD4+ T cells184.  
Substantial evidence has implied the importance of cellular T cells in pertussis immunity. Of 
note, the distinctly polarized T cell subtypes influence the quality of protection differently 
(Figure 9). It has been well-evidenced that Th1 and Th17 cells appear to be more effective at 
conferring protection than Th2 cells185. Natural infection or wPV immunization was shown to 
induce Th1 and/or Th17 CD4+ T cells, but no or limited Th2 cells186,187. Animal studies showed 
that IFN-γ-/- or IL-17A-/- mice were not able to clear B. pertussis infection, which proved the 
importance of Th1/Th17 cells in this scenario186,188. In line with this, T cells isolated from 
infants diagnosed with pertussis or at convalescent stage secreted IFN-γ and IL-2, but no or 
very limited level of IL-4 and IL-5189. In addition to the systemic T cell responses, emerging 
studies have focused on tissue-resident memory T (TRM) cells in the context of pertussis. In B. 
pertussis-infected mice, a population of IL-17 and IFN-γ-producing CD4 TRM cells were 
induced in the lung and these cells quickly expanded upon secondary infection190. Importantly, 
passive transfer of isolated CD4 TRM cells conferred a level of protection in the recipient mice. 
Similar results were described in wPV-immunized mice that showed a development of IL-17 
and IFN-γ-producing CD4 TRM cell response within the respiratory compartment191. In contrast 
to natural infection or wPV immunization, aPV immunization mainly induces a Th2-biased T 
cell response. However, it has been shown that IL-4-/- mice and wide type mice could clear B. 
pertussis infection at a similar rate upon virulent challenge, suggesting that Th2 cells are not 
essential to control pertussis186. Moreover, aPV immunization was not able to generate CD4 
TRM cells in the lung as that by wPV immunization or natural infection191.  
T cell responses elicited by the live vaccine BPZE1 have also been studied. It has been shown 
that BPZE1 could induce Th1 and Th17 cellular responses in mice similar to natural infection. 
IL-17 and IFN-γ-producing CD4 TRM cells also appeared at nasal sites upon BPZE1 
immunization192. In Paper III, we detected a Th1 CD4+ T cell response in the blood induced 
by BPZE1193. While Th17 cells were not detectable in the circulation, they may be elicited but 
reside in the airway mucosa.  
Finally, although early studies indicated that CD8+ T cells are not needed for the protection 
against pertussis184. Recent evidence proposed a potential role of cytotoxic CD8+ T cells, 
especially due to the intracellular infection properties of B. pertussis162. IFN-γ-producing CD8+ 
T cells were shown to be induced in B. pertussis-infected individuals194. A booster with aPV 
was able to generate pertussis-memory CD8+ T cells195. Anyhow, IFN-γ secreted from 
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activated CD8+ T cells may help control the infection by activating innate effector cells such 
as neutrophils and macrophages. 
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6 MATERIALS AND METHODS 
Detailed information is available in the results and discussion session, and in the papers.  
6.1 IMMUNIZATIONS 
All animal studies in this thesis were approved by the Animal Care and Use Committees of the 
Vaccine Research Center, National Institutes of Health (Paper I), or the Stockholm Local 
Ethical Committee on Animal Experiments (Paper II). Approval for human studies in Paper 
III was granted by the Swedish Medical Product Agency (MPA) and the Stockholm Local 
Ethical Committee. 
In Paper I, Indian rhesus macaques were immunized with 100µg of recombinant HIV-1 
envelop glycoprotein (Env) (TV1 strain, Novartis) in adjuvant via i.m. injection at 0, 4, 12 and 
24 weeks. After one and half years, the animals received a boost immunization with Alexa 
Fluor 680 labeled Env (AF680-Env, 100µg) in one arm and PBS in the contralateral arm as 
control. In Paper II, Chinese rhesus macaques were i.m. immunized with a vaccine (50µg) 
composed of mRNA encoding for the hemagglutinin (HA) of H10N8 influenza A virus 
formulated in a lipid nanoparticle (LNP) at 0 and 4 weeks. For vaccine tracking experiments, 
the animals received vaccination with an Atto-655 labeled LNP/mCitrine mRNA vaccine 
(50µg) in one arm and PBS in the contralateral arm as control. In Paper III, the human clinical 
trials were registered in ClinicalTrial.gov, NCT02453048 (BPZE1 vaccine study) and 
NCT00870350 (Tetanus, diphtheria, and pertussis, Tdap5 vaccine study). In BPZE1 vaccine 
study, healthy adults (18-32 years of age) received a single intranasal administration with 109 
colony forming units (CFU) of BPZE1 in a volume of 0.4 mL per nostril. In Tdap5 vaccine 
study, adolescents (14-15 years of age) with a vaccination history of three primary 
immunization of DTaP5 (at 3, 5, and 12 months of age) plus a boost immunization of Tdap5 
(at 5.5 years of age) received another booster dose of Tdap5. DTaP5 and Tdap5 vaccines 
contain the same components. Pertussis vaccine is composed of 5 protein antigens including 
FHA, PT, PRN, FIM2, and FIM3. Tdap5 has a reduced dose of the diphtheria and pertussis 
vaccine antigens compared to DTaP5.  
6.2 SAMPLING AND CELL ISOLATION 
In Papers I-II, muscle tissues of the injection site and injection site draining LNs were collected 
and processed to obtain single cell suspension as previously described26,196. In Papers I-III, 
human and rhesus PBMCs were isolated from fresh blood using Ficoll (GE Healthcare) 
gradient centrifugation. Human monocytes and neutrophils were isolated from fresh peripheral 
blood using RosetteSep™ Human Monocyte Enrichment Cocktail (STEMCELL Technology) 
and Polymorphophrep solution (Axis-Shield), respectively. For cell sorting experiments, 
different cell populations were purified using fluorescence-activated cell sorting (FACS) or 
magnetic-activated cell sorting (MACS). 
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6.3 FLOW CYTOMETRIC ANALYSIS 
Cells were washed and stained with LIVE/DEAD Fixable Blue Dead Cell Stain Kit 
(ThermoFisher Scientific) prior to incubation with human FcR blocking reagent and antibody 
cocktails for 20 min at room temperature (RT) in the dark. Intracellular staining of cytokines 
was performed using Fixation/Permeabilization Kit (BD Bioscience) according to the manual. 
Flow cytometric analysis was carried out on LSRFortessa cell analyzer (BD Biosciences). Data 
was analyzed using FlowJo V.10.1 (Tree Star). 
6.4 ANTIGEN PRESENTATION ASSAY 
Different subsets of APCs were loaded with antigens for 1h and then co-cultured with 
carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled autologous purified CD4+ T 
cells at a ratio of 1: 10. After 5 days of culture, proliferation of CD4+ T cells was measured by 
flow cytometry.  
6.5 ANTIBODY ELISA ASSAY 
96-well half-area plates (Greiner bio-one, Germany) were coated with antigens or bacterial 
lysates overnight at 4°C. Serum samples were diluted in PBS-T containing 0.2% BSA prior to 
incubation at RT. Total IgG was evaluated using HRP-conjugated mouse anti-human IgG. IgA 
and IgG subclasses were evaluated using mouse anti-human IgA, IgG1, IgG2, IgG3, IgG4 and 
further analyzed with HRP-conjugated sheep anti-human IgG (Jackson). TMB Substrate 
(Biolegend) was used for development and the absorbance was read at 450nm (minus 550nm 
for wavelength correction).  
6.6 MEMORY B CELL ELISPOT 
In Paper III, antigen-specific memory B cells were evaluated by ELISpot. MAIPSWU 96-well 
plates (Millipore) were coated with vaccine antigens. PBMCs were stimulated for 4 days to 
expand memory B cells and then added to the respective wells for 24h culture, followed by 
sequential incubation with biotinylated goat anti-human IgG or IgA and streptavidin-
conjugated alkaline phosphatase. Spots were developed with BCIP/NBT substrate (Mabtech) 
and counted using an AID ELISpot Reader (Autoimmun Diagnostika). Results were depicted 
as spot-forming cells (SFC) per million stimulated cells.   
6.7 ANTIBODY OPSONIZATION ASSAY 
107 CFU of live BPZE1 were incubated with pooled serum from vaccinees at 37°C for 25min, 
followed by co-culture with fresh human neutrophils (1x106 cells). After 1h of incubation, cells 
were evaluated by flow cytometric analysis to evaluate the activation and maturation. 
Production of reactive oxygen species was measured using cellular ROS Assay Kit (Abcam) 
according to the manual.   
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6.8 2-DIMENSIONAL IMMUNOBLOTTING 
Isoelectric focusing (IEF) was performed to separate protein of bacterial lysates by the 
difference in isoelectric point using an Ettan IPGphor 3 IEF system (GE Healthcare). After 
IEF, 12.5% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) was 
performed to further separate the proteins by molecular weight. After SDS-PAGE, proteins 
were transferred to polyvinylidene difluoride (PVDF) membrane in a Trans-Blot Turbo 
Transfer System (Bio-Rad). The membrane was blocked in 5% skim milk overnight at 4°C, 
followed by sequential incubation with pooled serum. For IgG detection, membrane was 
incubated with HRP-conjugated mouse anti-human IgG. For IgA detection, membrane was 
incubated with mouse anti-human IgA followed by incubation with HRP-conjugated sheep 
anti-mouse IgG. After all incubations, the signals were visualized using Amersham ECL Prime 
Western Blotting Detection Reagent (GE Healthcare) under ChemiDoc MP Imaging System 
(Bio-Rad). 
6.9 LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (LC-MS) 
Protein spots were excised manually from CBB G250-stained acrylamide gel and placed in 
Eppendorf tubes for in-gel digestion. Following sequential washing, reduction, alkylation and 
digestion, the tryptic peptides were acidified and further cleaned up on C-18 Stage Tips 
(Thermo Scientific). The reconstituted peptides were first separated on a 50 cm long EASY-
spray column (Thermo Scientific) connected to an Ultimate-3000 nano-LC system (Thermo 
Scientific). Mass spectra were acquired on a Fusion Orbitrap mass spectrometer (Thermo 
Scientific) for full mass, followed by data-dependent HCD fragmentations from most intense 
precursor ions. The tandem mass spectra were acquired and analyzed using the Mascot search 
engine v.2.5.1 (Matrix Science Ltd., UK) and searched against B. pertussis protein database 
from UniProt (6,516 entries). Initial search results were filtered with 5% FDR using Percolator 
to recalculate Mascot scores. 
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7 RESULTS AND DISCUSSION 
7.1 NEUTROPHILS PRESENT VACCINE ANTIGENS TO COGNATE MEMORY 
T CELLS (PAPER I) 
Several early studies demonstrated that neutrophils could acquire the antigen-presenting 
function upon cytokine stimulation in vitro58,59. These findings were overlooked for a long time 
mainly because of the assumed short lifespan of neutrophils. However, emerging evidence has 
shown that neutrophils can survive much longer than originally thought. Their half-life was 
estimated to range from 13 to 19 hours in vivo under homeostasis and to be even longer in non-
homeostatic conditions197,198. Apart from that, several studies including ours have shown that 
upon infection or vaccine injection, neutrophils are the first and most abundant cells that 
migrate to the sites of infection/injection, take up the antigens, and transport them to secondary 
lymphoid organs such as LNs26,170,199. Based on that, we speculated that neutrophils may play 
a role in regulating T cell responses if they could act as APCs. The first study (Paper I) in my 
Ph.D. work therefore revisited this topic and found evidence to support that neutrophils can 
function as APCs in vitro and ex vivo.  
First, we assessed the antigen-presenting function of human neutrophils in a side-by-side 
comparison with several other APC subsets. We established a flow cytometry-based approach 
to isolate distinct DC subsets, monocytes, neutrophils, and CD4+ T cells with high purity from 
healthy cytomegalovirus (CMV)- or influenza virus- seropositive individuals. The sorted APC 
subsets and neutrophils were pulsed with CMV pp65 antigens or influenza HA antigens, 
followed by co-culture with autologous CFSE-labeled CD4+ T cells for 5 days. We found that 
BDCA-1+ myeloid DCs (MDCs) being classical potent APCs demonstrated superior capacity 
to present the antigens and stimulate antigen-specific T cell proliferation. Two subsets of 
monocytes (CD14+ monocytes and CD14-CD16+ monocytes) showed moderate to high 
antigen-presenting ability. Neutrophils and plasmacytoid DCs (PDCs) demonstrated low but 
persistent capacity to present the antigens and induce antigen-specific T cell proliferation 
(Figure 10A).  
 
Figure 10. (A). Antigen presentation by distinct APC subsets and neutrophils. (B). Antigen 
presentation by neutrophils is dependent on HLA-DR. 
Engagement between the MHC-II-peptide complex on APCs and T cell receptor (TCR) on T 
cells is indispensable for the induction of antigen presentation200. The observed antigen 
presentation by neutrophils was also mediated by HLA-DR on neutrophils as the presence of 
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HLA-DR neutralizing antibodies dramatically reduced T cell proliferation (Figure 10B). 
However, we and others have shown that fresh neutrophils are devoid of HLA-DR on the cell 
surface201, which we found was further supported by their inability to elicit a mixed lymphocyte 
reaction (MLR) when co-cultured with allogeneic T cells (Figure 11A).  
 
Figure 11. (A). Neutrophils cannot drive allogeneic T cell proliferation in a MLR system. (B). 
Neutrophils acquire the expression of HLA-DR, CD40 and CD80 when co-cultured with 
autologous CD4+ memory T cells and cognate antigens. 
This raised the question of how neutrophils acquired the expression of HLA-DR to suffice them 
as APC. Using cells from CMV-seropositive individuals, we found that neutrophils expressed 
a marked level of surface HLA-DR and costimulatory molecules (CD40 and CD80) when they 
were incubated with autologous CD4+ T cells and cognate pp65 antigens (Figure 11B). Of note, 
expression of these APC machinery on neutrophils required the presence of both antigens and 
antigen-specific memory T cells. These molecules were not induced on neutrophils that had 
been cultured with T cells or antigens alone, or with T cells in the presence of irrelevant 
antigens such as ovalbumin (OVA). Neither were they induced when using cells sorted from 
CMV-seronegative donors.  
To further evaluate the antigen-presenting function of neutrophils ex vivo, we utilized rhesus 
macaques that had received previous immunizations with the HIV-1 vaccine candidate Env 
glycoprotein and developed Env-specific memory T cell responses. We re-immunized the 
animals with AF680-Env and isolated the AF680-Env+ neutrophils and MDCs from vaccine 
draining LNs (dLNs) at 24h after injection (Figure 12A). As control, neutrophils and MDCs 
were isolated from PBS dLNs after receiving PBS injection in the contralateral arm. After a 5-
day co-culture of autologous CD4+ T cells and AF680-Env+ neutrophils, we found that 
neutrophils that had taken up the vaccine antigens were able to induce robust proliferation of 
CD4+ T cells through antigen presentation (Figure 12B). As expected, AF680-Env+ neutrophils 
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showed a much higher expression of HLA-DR than neutrophils sorted from PBS dLNs (Figure 
12C). 
 
Figure 12. (A). Experiment design for the evaluation of antigen presentation ex vivo. (B). Env+ 
neutrophils and MDCs could present antigens to antigen-specific T cells. (C). Env+ neutrophils 
showed a higher level of HLA-DR than neutrophils sorted from PBS dLN.    
Collectively, this study demonstrated that neutrophils can acquire antigen-presenting function 
and can be thought of as atypical APCs. However, the physiological significance remains 
elusive. In the context of vaccination, as neutrophils are the predominant cells transporting 
vaccine antigens to LNs they may be able to play a considerable role to act as APCs to activate 
memory T cells. Although their antigen-presenting capacity cannot be compared with that of 
classical APCs, their abundance may compensate for some of their weakness. However, the 
considerable uptake of administrated vaccine antigens by neutrophils may lead to a shortage of 
antigens for other classical APCs, thus resulting in less efficient generation of T cell 
responses202. Nevertheless, another possibility is that even if neutrophils internalize a large 
proportion of the administrated antigens and fail to present them timely, these antigens may be 
re-captured in the form of apoptotic neutrophils in the end by adjacent APCs. Therefore, the 
role that neutrophils play in regulating vaccine-specific T cell responses is intriguing and merits 
further investigation.  
7.2 RHESUS MDSCS ARE INDUCED BY VACCINE ADMINISTRATION (PAPER 
II) 
Heterogeneity of neutrophils has recently been described in many diseases35. In addition to the 
immune-stimulatory functions such as antigen presentation that we studied in Paper I, some 
neutrophils, for example the subpopulation known as PMN-MDSCs203, exhibit immune-
suppressive functions. In the vaccine field, much focus so far has been put on understanding 
how vaccines stimulate immune response, but little is known about the negative immune 
regulators. Information on whether MDSCs change in response to prophylactic vaccination and 
whether they can suppress the stimulation of vaccine responses is extremely limited. Therefore, 
in Paper II, using NHP as experimental model, we studied these suppressive PMN-MDSCs as 
well as M-MDSCs with the aim to understand their role in the context of vaccination.  
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Figure 13. Phenotypic identification of MDSCs in rhesus PBMCs by flow cytometry. 
In contrast to the MDSCs in humans and mice76, the knowledge of MDSCs in NHPs is very 
limited. A few studies on MDSCs in rhesus macaques have been published, but the information 
on the phenotypes of these cells is variable and even conflicting between studies102,204,205. 
Therefore, the first aim of this study was to establish a method to identify rhesus MDSCs to 
ensure an accurate monitoring of these cells. We established a staining panel of antibodies for 
the phenotyping of rhesus MDSCs using flow cytometry, and further developed a strategy to 
functionally characterize them based on their suppressive functions. We found that M-MDSCs 
and PMN-MDSCs exist in rhesus blood 
at steady state, which can be identified 
as HLA-DR-Lin-CD14+CD11b+ cells 
and HLA-DR-CD66abce+CD33+ LDNs, 
respectively (Figure 13). Importantly, 
both M-MDSCs and PMN-MDSCs 
exerted strong inhibitory activities on T 
cell proliferation in vitro, which 
confirmed their suppressive function 
(Figure 14).  
To monitor the MDSCs at early time 
points after vaccinations, we utilized 
animals that had received an mRNA 
vaccine encoding for the influenza 
HA antigen of an H10 strain and 
developed well-detectable H10-
specific T cell and antibody responses. Blood samples from these animals were used to analyze 
the frequencies of MDSCs. Before termination, the animals also received i.m. injections of the 
vaccine or PBS in separate arms. This gave us the opportunity to analyze MDSCs in multiple 
tissue compartments. Prior to and at 24h after injection, the frequencies of MDSCs at different 
compartments were measured, including blood, injection site (muscle tissue), as well as 
injection site dLNs (Figure 15). We found that M-MDSCs transiently increased in the blood 
and vaccine injection site at 24h post vaccine administration, accompanied by an increase of 
Figure 14. PMN-MDSCs and M-MDSCs suppress T 
cell proliferation. SEB: staphylococcal enterotoxin B. 
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non-suppressive CD14+ monocytes as we reported earlier170. We also detected a clear 
infiltration of monocytes into the vaccine-dLNs, but not for M-MDSCs. Both PMN-MDSCs 
and the counterpart non-suppressive CD33- LDNs showed a trend of increase in the blood. A 
clear infiltration of SSChighCD66abce+ neutrophils in vaccine injection site and vaccine dLNs 
was also observed. But due to the limited information about the phenotype of tissue PMN-
MDSCs, we could not further distinguish them from other neutrophil subsets. Further, through 
transcriptomics analysis of MDSC-related genes in the injection site biopsies, we found that a 
wide range of genes involved in the expansion, functions, and migration of MDSCs were 
expressed at a much higher level in vaccine injection site than the control PBS injection site.  
 
Figure 15. Frequencies of MDSCs, CD14+ monocytes, and neutrophils subsets in the blood, 
injection sites, and the corresponding dLNs at day 1 post injection.   
While we showed that MDSCs were induced after vaccination, these cells only increased 
transiently at an early time point (day 1) and had returned to pre-vaccination level after 7 days. 
Importantly, despite the finding of an increase of MDSCs, the generation of adaptive vaccine 
responses was successful and showed well-detectable specific T cell and antibody responses, 
which suggest that any suppressive capacity these cells exert is not detrimental to the induction 
of vaccine responses. Vaccine administration usually generates a robust level of local or 
systemic inflammation that favors the induction of immune responses. However, this type of 
inflammation needs to resolve timely to avoid excessive inflammation, otherwise leading to a 
high reactogenicity or even autoimmune reactions. We therefore speculate that the early 
generation of MDSCs is a reaction of immune system to counteract the inflammatory reactions 
and therefore plays an important role in the context of vaccine administration. 
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7.3 A LIVE B. PERTUSSIS VACCINE BPZE1 ELICITES TH1 TYPE BROAD 
ANTIBODY RESPONSES IN HUMANS (PAPER III) 
As mentioned earlier, control and prevention of pertussis remain to be an important public 
health issue due to the rise of pertussis cases during the past years15. Although the currently 
used aPV confers protection against disease, the rapid waning of aPV-induced immunity and 
inability to block nasal colonization and thereby reduce transmission compared to wPV are 
believed to cause the resurgence of pertussis206,207. There is therefore a critical need for a better 
pertussis vaccine with high efficacy.  
To this end, a live attenuated BPZE1 candidate pertussis vaccine has been developed over 
several years144. This BPZE1 strain was developed through three genetic modifications with 
the aim to remove DNT, inactivate PT and markedly reduce the production of TCT. In animal 
models, BPZE1 demonstrated excellent efficacy evidenced by the generation of mucosal and 
systemic immune responses, long-lasting protection, and the prevention of nasal colonization 
upon virulent challenge145,192. Clinical phase I trials in humans were initiated in Sweden as 
Sweden had suspended pertussis vaccination for several years (1979-1996) and therefore 
human study subjects who were vaccination naïve were available. BPZE1 was provided by 
ILiad Biotechnologies, USA and the clinical studies were led by the Public Health Agency of 
Sweden. In humans, BPZE1 was found to show good safety and dose-escalating studies 
showed promising immunogenicity and colonization in the nasal cavity147. We were contacted 
to assist in the work to further dissect the immune responses induced by BPZE1 in humans, 
which expanded into a large project where we performed multiple analyses to evaluate a wide 
range of immune responses to BPZE1, with particular focus on the antibody profiles (Figure 
16). In addition, since BPZE1 is an anti-bacterial vaccine, it offered us an opportunity to further 
study how antibodies cooperate with myeloid effector cells such as neutrophils to clear the 
infection. We also compared the magnitude and quality of antibodies in the BPZE1 vaccinees 
with that induced by the standard aPV immunization, which helped us to obtain mechanistic 
insights into immune functions important for pertussis protection and control.  
 
Figure 16. Study design of the evaluation of BPZE1 responses in humans. 
We found that BPZE1 administration induced an early transient increase of plasmablasts and 
activated Th1-type circulating T follicular helper (cTfh1) cells in the blood (Figure 17A), which 
indicated that an antibody response was generated rapidly following BPZE1 immunization. In 
addition, the expansion of activated cTfh1 cells in the BPZE1 vaccinees suggested that BPZE1 
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may preferentially induce a Th1-polarized T cell response. We therefore performed an 
intracellular cytokine recall assay to evaluate the subtype of BPZE1-specific T cells. At 28 days 
after vaccination, a dominant Th1-biased CD4+ T cell response was detected in the BPZE1 
vaccinees, evidenced by an increase of TNF- or IFN-γ-producing BPZE1-specific T cells. No 
or very limited numbers of BPZE1-specific Th2 (IL-13) or Th17 (IL-17A) cells were detected 
(Figure 17B). 
 
Figure 17. BPZE1 vaccination induces an early increase of (A) plasmablasts and activated 
cTfh1 cells at day 4-14, and (B) BPZE1-specific Th1-biased CD4+ T cells at day 28. 
The polarization towards a Th1 response by BPZE1 immunization was further evaluated by 
characterizing the antibody responses. We measured the titers of antibodies including different 
Ig isotypes and subclasses, and benchmarked the responses in the BPZE1 vaccinees to the 
responses induced by aPV immunization. At 28 days after immunization, BPZE1 vaccinees 
showed significantly increased total IgG and IgA titers against BPZE1 lysates. The increase of 
total IgG was exclusively contributed by IgG1 and IgG3 subclasses indicating a Th1-biased 
phenotype. No increase of IgG2 was observed while IgG4 was not detectable. When evaluating 
the antibody responses at 28 days after the 5th vaccination of aPV, we found that aPV induced 
all four IgG subclasses. The IgG2 and IgG4 responses exclusively detected in the aPV group 
indicated a more Th2-skewed response compared to the BPZE1 group.  
 
Figure 18. Administration of BPZE1 and aPV induces different types of antibodies in humans 
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Next, we combined 2D immunoblotting with LC-MS to characterize binding specificities of 
the antibodies in BPZE1 and aPV vaccinees. This technique also enabled the identification of 
novel immunogenic antigens. As expected, BPZE1 containing the full spectrum of antigens 
was shown to induce a much wider repertoire of antibodies with multiple binding specificities 
compared to the aPV (Figure 19A). Both BPZE1-induced IgG and IgA were found to target 
multiple distinct antigens. In contrast, aPV-elicited IgG was directed primarily against the 
vaccine components. aPV-elicited IgA was directed against a few antigens such as PRN, BrkA, 
DnaK and Enolase, the latter three of which are not included in the vaccine formulation. This 
is likely the result of natural exposure to B. pertussis or other pathogens exhibiting the same 
antigens since aPV is unable to induce IgA responses in naive individuals179,181. In addition to 
PT, FHA, and PRN included in aPV, multiple immunogenic antigens were identified in this 
study (Figure 19B). Several of them have previously been shown to be immunogenic in either 
animal or human studies179,208-210.  
 
Figure 19. Immunoprofiling of antibody responses in BPZE1 and aPV vaccinees and 
identification of novel immunogenic antigens. 
As described in Figure 6, antibodies work through three major mechanisms. Since the bacterial 
clearance is largely mediated by phagocytic cells such as neutrophils, we assessed whether the 
antibodies induced by BPZE1 and aPV have different abilities to opsonize bacteria and mediate 
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killing by neutrophils. We found that neutrophils exposed to live BPZE1 opsonized by BPZE1-
induced antibodies showed a much higher level of ROS, the molecules heavily involved in 
bacteria killing, as well as increased expression of cell activation markers CD11b and CD66. 
Bacterial opsonization by aPV-induced antibodies also led to the activation of neutrophils, 
indicated by elevated expression of CD11b and CD66. However, ROS production was not 
increased (Figure 20A). By using heat inactivated (HI)-serum in which complement activity is 
destroyed for the analysis, we found that HI-serum opsonized BPZE1 did not reduce the level 
of ROS production in neutrophils, which means that Fc-receptor-mediated opsonophagocytosis 
play a dominant role in triggering ROS production (Figure 20B). Further, we evaluated 
neutrophil killing activity following antibody-mediated bacterial opsonization. An enhanced 
killing activity by neutrophils was found when using BPZE1-induced antibodies to opsonize 
the bacteria. In contrast, aPV-induced antibodies did not show this effect consistent with their 
inability to stimulate ROS production (Figure 20C). One potential mechanism why the aPV-
induced antibodies could not stimulate ROS production may be related to the release of ACT 
by B. pertussis, which is known to inhibit ROS production of neutrophils166. By ELISA we 
found that the BPZE1 vaccinees showed significantly increased titers of IgG1, IgG3 and IgA 
antibodies against ACT, which could potentially have resulted in neutralization of ACT and 
alleviating any inhibition on ROS production. In contrast, the aPV vaccinees did not show 
induction of ACT-specific antibodies (Figure 20D). This may, at least partly, explain the 
inability of aPV-induced antibodies to stimulate ROS production. Collectively, these data show 
that BPZE1 is superior over aPV at inducing effective opsonizing antibodies leading to an 
enhanced bactericidal activity of neutrophils.  
 
Figure 20. (A-C). BPZE1 is superior over aPV at inducing opsonizing antibodies leading to an 
enhanced ROS production and bactericidal activity by neutrophils. (D). BPZE1 elicits robust 
levels of IgG1, IgG3 and IgA in humans. 
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In conclusion, this study provides novel findings on increased antibody breadth and bacterial 
killing functions induced by BPZE1 compared to aPV. Importantly, novel immunogenic 
antigens in BPZE1 were identified, which may represent critical antigens to generate better 
protection against pertussis disease and transmission. An intranasal immunization with a live 
pertussis vaccine is likely in a better position to stimulate both effective mucosal and systemic 
protective responses comparable to what the natural infection generates. Upon intranasal 
delivery into the host (Figure 21), BPZE1 first colonizes at the nasal cavity, activates local 
resident cells, generates inflammation, and primes the innate immune system. Th1-polarized 
antibody responses and cellular responses are subsequently generated and constitute both 
mucosal and systemic line of defense. A well-established Th1 type immune system favors the 
clearance of infection and prevention from disease or transmission. This can be attributed to 
the highly efficient collaboration between Th1-type antibodies (IgG1, IgG3) and innate effector 
cells, as well as the strong ability of Th1 cytokines (IFN-γ, IL-12) in activating innate cells.  
 
Figure 21. Steps in BPZE1 inducing immunity 
This study does not only demonstrate promising improved immunity by a new vaccine 
candidate but will also hopefully increase the overall basic understanding of the immunological 
mechanisms critical for pertussis protection and control. 
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8 CONCLUDING REMARKS 
Rational vaccine design relies on a comprehensive understanding of the immune mechanisms 
dictating vaccine responses. This thesis aiming to expand such knowledge has particularly 
focused on the myeloid cells and antibodies.  
Innate immune system being the first unit interacting with vaccines is believed to 
fundamentally affect the later generation of adaptive responses, and ultimately determines the 
vaccine outcomes. Neutrophils being the major member of innate system are not only 
phagocytic cells eliminating pathogens, but also possess versatile abilities in orchestrating 
adaptive immunity, for example, the antigen-presenting function as described in this thesis. 
Although innate immune activation is critical for the induction of adaptive responses, “Too 
much is as bad as not enough.” Activation of innate responses has to be well controlled to an 
appropriate degree that can lead to an efficient adaptive response and at the same time ensure 
the safety. To this end, negative immune regulators, such as MDSCs, are needed. Therefore, 
defining the role of different myeloid cells in vaccination may aid in the development of novel 
vaccination strategies through manipulating or targeting these cells. 
Most vaccines so far work by inducing antibodies for the protection against infectious diseases. 
In the context of B. pertussis infection, Th1 type antibodies can efficiently interact with innate 
effector cells to facilitate their anti-bacterial functions and therefore are important for a 
successful pertussis vaccine. Both the magnitude (antibody titer) and the type of immune 
responses needed for the control and protection of B. pertussis infection must be taken into 
consideration for rational vaccine design.  
The main conclusions of the three studies in this thesis are: 
I. Neutrophils can present antigens to cognate memory T cells and thus are referred 
to as atypcial APCs (Paper I). 
 
II. MDSCs that are elicited early after vaccine administration may play a counter-
balancing role to prevent excessive inflammation (Paper II). 
 
III. A live pertussis vaccine BPZE1 can elicit Th1 type antibodies with broad antigen-
binding specificity and potent bacterial opsonizing activity (Paper III). 
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